Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

SEC Filings

Search
Filing date Form Description View
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-21-002668.pdf
0001179110-21-002668.rtf
0001179110-21-002668.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-21-002663.pdf
0001179110-21-002663.rtf
0001179110-21-002663.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-21-002672.pdf
0001179110-21-002672.rtf
0001179110-21-002672.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-21-002666.pdf
0001179110-21-002666.rtf
0001179110-21-002666.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-21-002677.pdf
0001179110-21-002677.rtf
0001179110-21-002677.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-21-002211.pdf
0001179110-21-002211.rtf
0001179110-21-002211.xls
8-K

Report of unscheduled material events or corporate event

 View HTML
0001558370-21-001112.pdf
0001558370-21-001112.rtf
0001558370-21-001112.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
10-K

Annual report which provides a comprehensive overview of the company for the past year

 View HTML
0001558370-21-001141.pdf
0001558370-21-001141.rtf
0001558370-21-001141.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
S-8

Securities offered to employees pursuant to employee benefit plans

 View HTML
0001558370-21-001147.pdf
0001558370-21-001147.rtf
0001558370-21-001147.xls
SC 13G/A

An amendment to the SC 13G filing

 View HTML
0000080255-21-001228.pdf
0000080255-21-001228.rtf